Why is current disease coding insufficient for rare pathologies?
Standard medical coding systems often fail to capture the specific nuances required to track rare conditions accurately. While the International Classification of Diseases (ICD-10) is the global standard, it frequently records the immediate symptom or the reason for a hospital visit rather than the underlying rare cause. This distinction is vital because a patient might be known to their physician, but their specific diagnosis remains invisible within the broader digital health infrastructure.
In Greece, the scale of this issue is significant. It is estimated that approximately half a million people suffer from some form of rare disease in the country, yet only half of them are actually diagnosed. Furthermore, while there are an estimated 9,000 rare diseases recorded internationally, only about 1,200 to 1,300 have been identified among diagnosed patients in Greece. This massive discrepancy highlights the limitations of current tracking methods.
This gap in data can lead to partial coverage for patients, as the system may not recognize the complexity of their needs. In Europe, healthcare systems have spent the last 25 years developing specialized codes to ensure that rare diseases are not lost in general classifications. Without these specific identifiers, it becomes nearly impossible to monitor the long-term journey of a patient or to plan the specialized services they require.
The limitation of ICD-10 in specialized care
The ICD-10 system is designed for broad epidemiological tracking and general billing. The application of new DRG (Diagnosis Related Group) hospital codes by KETECNY, which facilitates hospital payments via EOPYY instead of the state budget, has necessitated the characterization of diseases according to ICD-10 codes. However, this system often falls short for rare conditions.
Often, the system only records the finding that prompted the patient to seek medical attention, rather than the actual underlying disease that caused the symptom. For a patient with a genetic condition that manifests in childhood, a general code might only reflect a secondary complication. This lack of granularity prevents the healthcare system from seeing the 'full picture' of the patient's needs, potentially delaying access to specialized treatments or multidisciplinary care teams.
How will ORPHAcodes transform patient visibility?
The implementation of ORPHAcodes, through the European OD4RD3 (Orphanet Data for Rare Diseases) project, represents a significant shift toward precision in healthcare data. Unlike general codes, ORPHAcodes utilize the internationally recognized Orphanet nomenclature, allowing for much more granular identification of rare conditions. This ensures that a diagnosis is not just a clinical note in a doctor's office, but a searchable, interoperable data point within the national health system.
According to Dimitris Athanasiou, Vice President of the Hellenic Association of Rare Diseases (ESAE), an ORPHAcode is much more than a simple number. He states that it serves as the primary means for an individual with a rare condition to become visible within health system data. This visibility allows raw data to be converted into actionable knowledge, facilitating better planning, more effective research, and more equitable care for both patients and their families.
The introduction of these codes into the Greek health system is being coordinated by ODIPY, with the support of ESAE and in close cooperation with KETECNY, IDYKA, and other relevant bodies. The project includes training, the development of national expertise, and support for healthcare professionals. By using these codes, healthcare providers can ensure that the specific diagnosis is mirrored accurately in digital records. This interoperability is essential for creating datasets that can be compared across different regions and even across European borders, fostering a more unified approach to managing rare conditions.
What is the impact of coding on clinical care and service planning?
Precise coding is a prerequisite for effective healthcare resource management and the mapping of patient care pathways. When a health system knows exactly which patients live with specific rare conditions, it can better understand their unique requirements and design appropriate specialized services. This visibility allows authorities to identify where services are lacking and where they need to be expanded.
The use of specialized codes also facilitates better connections between local healthcare providers and specialized entities, such as National Centres of Expertise and European Reference Networks (ERNs). This connectivity ensures that patients are not just diagnosed, but are integrated into a network of specialists capable of managing their complex needs. For patients and their families, this 'visibility' means the healthcare system knows not just that a need exists, but exactly what that need is, how many people it affects, and where services must be developed.
Strategic planning through data
Beyond individual patient care, the data generated by accurate coding supports macro-level healthcare strategy. It allows for the mapping of 'care journeys,' helping administrators see where patients often get lost in the system or where diagnostic delays are most prevalent. This information is crucial for optimizing the allocation of specialized medical personnel and equipment.
The integration of ORPHAcodes will be combined with the development of specialized Rare Disease Registries to create a comprehensive data ecosystem. These registries aim to capture epidemiological data, the natural history of specific pathologies, the journeys patients take until diagnosis, the treatments provided, and the clinical outcomes of those treatments. This combination allows for the identification of the true, real-world needs of the patient population.
How do rare disease registries support medical research?
In Greece, the Ministry of Health has already begun establishing specialized registries for various fields, including rare hematological diseases, ophthalmology and vision, hepatology, neurology, and dermatology, as well as a specific registry for undiagnosed patients. In Europe, 24 such networks operate based on therapeutic categories.
Registries play a decisive role in clinical research, particularly in the development of new therapies. They help researchers assess the feasibility of clinical trials by identifying suitable patient populations and collecting essential data after a treatment has been released to the market. These registries can also assist in identifying appropriate patients for specific studies and monitoring the long-term safety and effectiveness of new interventions.
The importance of data for orphan drugs
For orphan drugs—medications specifically developed for rare diseases—real-world data is indispensable. Because the patient populations for these drugs are often extremely small, traditional large-scale clinical trials are difficult to conduct. Registries allow for the long-term monitoring of the safety and effectiveness of these treatments in a real-world setting, providing evidence that is vital for both regulatory approval and ongoing patient safety.
FAQ: Rare diseases coding and registries
What are ORPHAcodes?
ORPHAcodes are specialized identifiers based on the Orphanet nomenclature designed specifically for rare diseases. They provide much greater detail than standard ICD codes, allowing healthcare systems to identify specific rare pathologies accurately and ensure that patients receive the specialized care and recognition they require.
Why are rare diseases often under-diagnosed?
Under-diagnosis occurs because many rare diseases present with non-specific symptoms that are captured by general medical codes. Without specialized coding like ORPHAcodes, the underlying rare condition remains hidden in the data, preventing the healthcare system from recognizing the patient's true needs and providing appropriate specialized support.
How do registries help patients?
Registries help patients by improving the quality of care and accelerating research. They allow for better mapping of care pathways, ensure that specialized services are developed where they are most needed, and provide the necessary data to support the development and monitoring of new orphan drugs.
What is the role of the OD4RD3 project?
The OD4RD3 (Orphanet Data for Rare Diseases) project is a European initiative aimed at introducing ORPHAcodes into national health systems. In Greece, it is coordinated by ODIPY with support from ESAE and other agencies, with the goal of enhancing the visibility and management of rare diseases through better data.
Can coding improve access to specialized networks?
Yes, accurate coding facilitates better integration with European Reference Networks (ERNs). By ensuring a patient's diagnosis is clearly and accurately recorded, the system can more easily connect them with international networks of experts who specialize in their specific rare condition.
Key takeaways
- ORPHAcodes provide the granular detail necessary to identify rare diseases that standard ICD-10 codes often miss.
- The OD4RD3 project is actively working to integrate these specialized codes into the Greek healthcare system.
- Accurate coding enables better planning of specialized medical services and more efficient resource allocation.
- Disease registries are vital for clinical research and the long-term monitoring of orphan drug effectiveness.
The future of rare disease management
The transition toward specialized coding and comprehensive registries marks a turning point in how healthcare systems approach rare pathologies. By moving away from generic classifications and embracing the precision offered by ORPHAcodes, the medical community can move from reactive treatment to proactive, data-driven management. This evolution not only enhances the visibility of thousands of patients but also builds the foundational knowledge necessary to drive the next generation of medical breakthroughs and ensure that no patient remains invisible to the system.
